Trends News Trends In Small Cell Lung Cancer Incidence And Survival

GSK’227 Wins FDA Orphan Drug Designation in Small-Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan, for the treatment of small-cell lung cancer (SCLC), according to a news ... Read More

Imdelltra Improves Survival For Some With Small Cell Lung Cancer

Imdelltra improved overall survival in SCLC patients compared to chemotherapy, regardless of CFIs or prior anti-PD-(L)1 therapy. The DeLLphi-304 trial showed significant OS benefits with Imdelltra, ... Read More

Altering the daily timing of immunotherapy could improve survival in people with cancer

Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a study published in Cancer. Read More

AstraZeneca's ceralasertib-Imfinzi drug combo misses survival target in lung cancer trial

AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung ... Read More

Imdelltra Gains Traditional Approval for Extensive Stage Small Cell Lung Cancer

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ... Read More

BioNTech advances premarket as lung cancer candidate delivers survival edge

BioNTech SE (NASDAQ:BNTX) traded 3.1% higher in Monday’s premarket session after the company, alongside partner OncoC4, released encouraging survival data for its investigational lung cancer therapy, ... Read More

Timing of Immune Checkpoint Inhibitor Administration Affects Small Cell Lung Cancer Survival

Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival. Read More

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly ... Read More

New Treatments and Trends in Lung Neuroendocrine Carcinomas

Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ... Read More